



Discovery of Certain Organic Compounds as Targeted Anticancer Agents

Thesis
Presented by

Maiy Youssef Mohamed Jaballah

BSc. in Pharmaceutical Sciences (May 2002)

MSc. in Pharmaceutical Sciences (Pharmaceutical Chemistry) (December 2007)

Assistant Lecturer of Pharmaceutical Chemistry

Ain Shams University

Submitted in partial fulfillment of the

Doctorate of Philosophy Degree

In Pharmaceutical Sciences (Pharmaceutical Chemistry)

Under the supervision of

Khaled Abouzid Mohamed Abouzid

Professor and Chairman of Pharmaceutical Chemistry

Department

Faculty of Pharmacy

Ain Shams University

Nasser Saad Mohamed Ismail

*Professor of Pharmaceutical Chemistry
Faculty of pharmacy -Ain Shams University*

Rabah Ahmed Taha Serya

*Associate professor of Pharmaceutical Chemistry
Faculty of pharmacy -Ain Shams University*

Faculty of Pharmacy

Ain Shams University

2017

Acknowledgements

I owe my deepest appreciation and gratitude to **Professor Dr. Khaled Abouزيد Mohamed Abouزيد**, Professor and Chairman of pharmaceutical chemistry department, for his scientific supervision. I am really sincerely and profoundly indebted to him for his priceless guidance, endless support and immense knowledge during all stages of this work. I am heartily grateful to their indispensable opinion, real interest, invaluable advices, trust, caring, eminent guidance, and untiring help throughout the whole work. I truly thank him for his great efforts which allowed this thesis to appear in its final form.

I owe my truthful gratitude to Dr. Nasser Saad, Professor of Pharmaceutical Chemistry, and Dr. Rabah Taha; Associate professor of Pharmaceutical Chemistry for their keen and thorough revision of all thesis. I am heartily grateful to their guidance and help throughout the work.

I acknowledge with thankfulness all my colleagues in Pharmaceutical Chemistry Department, for their friendly cooperation, support and their continuous aid.

Also I would like to express my gratitude to the National Cancer Institute, Maryland, U.S.A for performing the in-vitro anticancer assay of the synthesized compounds.

Finally, I am profoundly indebted to my parents and my dear family for their unconditional love and aid, endless patience, understanding, encouragement and full support all throughout the whole long way.

Contents

Table of Contents

Acknowledgements	II
List of Figures	VI
List of Tables	VIII
List of Abbreviations	IX
1. Introduction	18
1.1 Cancer	18
1.1.1 Overview.....	18
1.1.2 Hallmarks of cancer.....	19
1.1.3 Causes of Cancer	21
1.2 Therapeutic approaches of cancer.....	22
1.2.1 Surgery	22
1.2.2 Radiation therapy	22
1.2.3 Chemotherapy	22
1.2.4 Hormonal therapy.....	23
1.2.5 Targeted therapy	26
2. Rationale and Design	44
2.1 SAR study of VEGFR-2 inhibitors	45
2.1.1 Strategies adopted for developing novel pyridazine-based scaffolds.....	48
2.2 Preliminary evaluation of the designed compounds using Molecular docking:	51
2.3 Synthetic schemes for synthesis of the designed compounds:.....	54
2.3.1 Scheme 1 for preparation of intermediates:.....	54
2.3.2 Scheme 2: Preparation of final compounds XIVa,b.....	56
2.3.3 Scheme 3: Preparation of final compounds XVII, XIXa-c	56
2.3.4 Scheme 4: Preparation of final compounds XXIIa-f	57
2.3.5 Scheme 5: Preparation of final compounds XXVIa-c	57
2.3.6 Scheme 6: Preparation of final compounds XXIXa-c, XXXa-c, XXXIa-c, XXXIII, XXVII	58

Contents

2.3.7	Scheme7: Preparation of final compounds XLa-e, XLla,b, XLII	60
2.3.8	Scheme 8: Preparation of final compounds XLIIla,b	61
3.	Results and Discussion.....	62
3.1	Chemistry.....	62
3.1.1	Scheme 1.....	62
3.1.2	Scheme 2.....	67
3.1.3	Scheme3.....	68
3.1.4	Scheme 4.....	72
3.1.5	Scheme 5.....	74
3.1.6	Scheme 6.....	77
3.1.7	Scheme 7.....	84
3.1.8	Scheme 8.....	88
3.2	Biological Evaluation.....	89
3.2.1	In vitro VEGFR-2 tyrosine kinase inhibitory activity	89
3.2.1.1	Initial screening at single dose of 10 μ M concentration.....	89
3.2.1.4	VEGFR2 investigational studies.....	97
3.2.2	In vitro antiproliferative activity against NCI 60-cell line.....	103
3.2.3	In vitro cytotoxic activity against T47D for selected compounds (IC ₅₀)	109
3.2.4	Effect of Compound XXIIe on apoptotic pathway: measuring the level of caspase 3.....	111
4.	ADMET study:.....	113
5.	Conclusion.....	119
6.	Experimental.....	121
6.1	Chemistry.....	121
6.1.1	Materials and instrumentation	121
6.1.2	Synthesis.....	122
6.2	Biological evaluation:.....	169
6.2.1	In vitro VEGFR-2 tyrosine kinase activity	170

Contents

6.2.2	In vitro Anti-proliferative activity against 60 cell line panel	171
6.2.3	In vitro HUVEC Anti-proliferative assay.....	173
6.2.4	Invitro T47D anti-proliferative assay.....	174
6.2.5	RNA extraction, Real time PCR analysis and quantification of active Caspase-3 gene expression.....	175
6.3	Molecular docking study.....	175
6.3.1	Protein preparation for docking.....	176
6.4	Field alignment.....	177
7.	References	178

List of Figures

List of Figures

Figure 1: Hallmarks of Cancer.	20
Figure 2: Causes of cancer.	21
Figure 3: Regulation of tumorigenic programming by activation of kinases.	27
Figure 4: Protein Kinase ATP binding site.	30
Figure 5: Protein kinase binding site; Active and Inactive confirmations.....	31
Figure 6: Four types of reversible binding mode.....	35
Figure 7: Tumor angiogenesis and inhibitors of VEGFR-2 signalling.	38
Figure 8: Small-molecule kinase inhibitors binding to the vascular endothelial growth factor receptor (VEGFR).	46
Figure 9: Bioisoteric modifications, optimization and development of pyridazine derivatives based on the starting point for the discovery of Sorafenib.....	49
Figure 10: Series 5	51
Figure 11: Binding mode of sorafenib (21) to VEGFR-2 hinge region through hydrogen bonding and hydrophobic interaction ¹¹¹	52
Figure 12: The bar graphs showing the HUVECs growth percentage after treatment with the target compounds.....	96
Figure 13: The alignment between the X-ray bioactive conformer of the lead compound (colored in red) and the docked pose of the same compound at VEGFR-2 binding site.....	98
Figure 14: Field alignment of compound XXIXb and Sorafenib showing similar molecular fields between the pyridazin-2-one (in XXIXb) and the pyridyl head group (in Sorafenib) suggesting a similar binding mode to VEGFR2.	103
Figure 15: Example of mean graph produced from NCI 60 cell line screening program. Mean graph of compound (XVIIIa) colour codes are given for each cell line.	104
Figure 16 : Caspase 3 RT-PCR for compound XXIIe; exhibiting Caspase 3 concentration in IU/ml.....	112

List of Figures

Figure 19: Plot of human intestinal absorption (HIA) and blood brain barrier plot for the newly synthesized compounds.	116
Figure 20: VEGFR-2 SAR study of the synthesized compounds; (a) Series 3; (b) series 4.	120
Figure 21: SAR studies of T47D antiproliferative activities of (a) Series 3; (b) Series 5.	120

List of Tables

List of Tables

Table 1: Classes of aromatase inhibitors.....	24
Table 2: FDA approved small molecules VEGFR-2 inhibitors.....	39
Table 3: Docking energy and amino acids involved in the binding interactions of some of the designed compounds representing each series (1 to 5).....	52
Table 4: Percent inhibition of VEGFR-2 enzymatic activity achieved by the targeted compounds at 10 μ M.....	89
Table 5: The IC ₅₀ values for compounds (XXIIb, XXVIb, XXIXa, XXIXb and XXXVII). ...	94
Table 6: The effect of compounds (XXIIb, XXVIb, XXIXa, XXIXb and XXXVII) on HUVEC proliferation at 10 μ M.	96
Table 7: Molecular docking investigational studies on VEGFR2	99
Table 8: Cell growth percentage of NCI 60 cancer cell lines exhibited by investigated final compounds (XIXa, XXVIc, XXIXb, XXIXc, XXXa,XXXb,XXXIb, XLa, XLb, XLe, XLIa, XLIb, XLII, XLIIa)	104
Table 9: The IC ₅₀ values of compounds (XXIIb, XXIId, XXIIe, XXXIb, XLb, XLe, XLd, XLe, XLIIb) of their anti-proliferative activity against breast cancer cell line T47D.	110
Table 11: Computer-aided ADMET screening of the synthesized compounds.....	117

List of Abbreviations

List of Abbreviations

Å: Angstrom

ABL: Abelson tyrosine kinase

ADMET: Absorption, Distribution, Metabolism, Excretion, and Toxicity study

ALK: Anaplastic lymphoma kinase

ANLL: Acute Non-Lymphocytic Leukemia

AIs: Aromatase Inhibitors

AQ Sol: Aqueous solubility

Asp: Aspartate

ATP: Adenine-5'-triphosphate

BBB: Blood brain barrier

BCR: breakpoint cluster region protein

BSA: Bovine serum albumin

BTK: Bruton's Tyrosine Kinase

°C: Celsius

C-Fms: Colony-Stimulating factor-1 receptor

C-kit: v-kit (Hardy-Zuckerman 4 feline) sarcoma viral oncogene

CHARMm: Chemistry at HARvard Macromolecular Mechanics

CNS: Central nervous system

CYP 450: Cytochrome P450

Cys: Cysteine

D₂O: Deuterium oxide

DFG: Aspartate- Phenylalanine- Glycine

DIPEA: Diisopropyl ethylamine

DMF: Dimethyl formamide

DMSO: Dimethyl sulfoxide

DNA: Deoxyribonucleic acid

EI-MS: Electron impact mass spectroscopy

EGFR: Epidermal growth factor receptor

ERA: Estrogen Receptor Antagonists

Fab: Fragment antigen-binding

FDA: Food and Drug Administration

FGFR: Fibroblast growth factor receptor

FLT: FMS-like receptor tyrosine kinase

FT-IR: Fourier transform-Infrared

Glu: Glutamate

HIA: Human intestinal absorption

His: Histidine

List of Abbreviations

Hrs: hours
HUVEC: Human umbilical vein endothelial cells
Hz: Hertz
IC₅₀: Half-maximal inhibitory concentration
IGFR: Insulin-like growth factor receptor
IRK: Insulin receptor kinase
ITK: Interleukin-2-inducible T-cell kinase
JAK: Janus kinase
KDa: Kilo Dalton
KDR: Kinase insert domain receptor
Lys: Lysine
Lck: Lymphocyte-specific protein tyrosine kinase
6-MP: 6-Mercaptopurine
m.p.: Melting point
Min: Minutes
MHz: Mega hertz
μM: Micromole
mmol: Millimole
μl: Microliter
MS: Mass spectroscopy
NCI: National Cancer Institute
NIH: National Institutes of Health
nM: Nanomole
NMR: Nuclear magnetic resonance
NRTK: Non-receptor tyrosine kinase
NSCLC: Non-Small Lung Cell cancer
PARP: Poly ADP ribose polymerase
Pd-C: Palladium on carbon
PDB: Protein data bank
PDGFR: Platelet derived growth factor receptor
PDT: Photodynamic therapy
Phe: Phenyl alanine
PM: Picometre
PPB: Plasma protein binding
Ppm: Part per million
PSA: Polar surface area
Psi: Pound per Square Inch
Raf: v-raf murine sarcoma viral oncogene
Ras: Rat sarcoma

List of Abbreviations

RMSD: Root mean square deviation

RNA: Riboneucleic Acid

rt: Room temperature

RTK: Receptor tyrosine kinase

SAR: Structure activity relationship

SMART: string matching algorithms research tool

SRC: Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene

TEA: Triethyl amine

THF: Tetrahydrofuran

Tie-2: Tyrosine kinase with immunoglobulin-like and EGF-like domains 2

TK: Tyrosine kinase

TKI: Tyrosine kinase inhibitors.

TLC: Thin layer Chromatography

VEGFR: Vascular endothelial growth factor receptor

Abstract

Cancer, or malignant tumor, is a myriad of diseases involving abnormal cell growth with the potential to invade or metastasize to other parts of the body. therefore, there is a need for newer treatment strategies with novel drugs acting at different pathways for treatment of malignancies.

Targeted therapies act by blocking essential biochemical pathways or mutant proteins that are required for tumour cell growth and survival. In the past few decades, protein kinases has drawn much attention as being of the most important drug targets for treatment of many diseases; especially cancer. Since, dysregulation and mutation in this family of ezymes play causal role in the development and maintenance of different types of cancer. Particularly, Vascular endothelial growth factor receptor-2 (VEGFR2) which is implemented in the maintanence of angiogenesis.

Angiogenesis; the growth of new blood vessels; is considered one of the important hallmarks of cancer. Hence there is a growing interest in VEGFR2 inhibition and its therapeutic implementation in cancer treatment in light of its unique ability to regulate cancer cell proliferation and metastasis through inhibiting angiogenesis, eventually leading to death of tumor cells.

In the current study, a series of pyridazine based scaffolds (**Series 1 to 5**) were designed and synthesized as VEGFR2 inhibitors. The design focused on exploration of the previous revealed SAR studies, bioisosteric modifications of the lead compounds both in market and in clinical studies as well as identification of the key interactions with the binding site *in silico*. The structures of synthesized compounds were confirmed by various spectral and microanalytical data.

Analysis of the VEGFR2 enzyme activity revealed that five of the synthesized compounds; namely (**XXIIb, XXVIb, XXIXa, XXIXb and XXXVII**) exhibited potent VEGFR2 inhibitory activity with IC₅₀ values equal to 1.8μM, 1.3μM, 1.4μM, 107nM, 60nM respectively. Moreover, the above compounds were further evaluated for their VEGF-stimulated proliferation of human umbilical vein endothelial cells (HUVEC) revealing moderate to potent inhibition at 10 μM concentration; especially **XXVIb** which displayed 99.82% inhibition.

Abstract

Evaluation of the anti-proliferative activities of the compounds were attempted. Fourteen of the final Compounds (**XIXa**, **XXVIc**, **XXIXb**, **XXIXc**, **XXXa**, **XXXb**, **XXXIb**, **XLa**, **XLb**, **XLe**, **XLIIa**, **XLIIb**, **XLII**, **XLIIIIa**) were selected by the National Cancer Institute “NCI” for single dose screening program at 10 μ M in the full NCI 60 cell panel. While the 6-chloropyridazine derivative (**XXXb**) showed remarkably the lowest cell growth promotion, hence good anti-proliferative activity against different cell lines compared to the rest of the compounds; it was noticed that compounds (**XLa**, **XLb**, **XLe**, **XLIIIIa**) demonstrated 71.4, 67.2, 64.6 and 47.2% growth inhibition almost exclusively against breast cancer cell line T47D.

Furthermore, nine of the synthesized compounds were evaluated for their antiproliferative activities against T47D cell line. Most of the investigated compounds showed IC_{50} in low nanomolar range; especially compounds (**XXIIe**) and (**XLd**) ; they displayed IC_{50} values of 0.75 and 0.94 respectively.

Since it was reported that the aromatase enzyme is overexpressed in breast cancer cell line T47D, thus, aromatase inhibitory activity was measured for compounds (**XXIIe**) and (**XLd**), which displayed 89 and 82% inhibitory activities respectively. These percent inhibition was superior to that of the reference drug ; Letrozole (aromatase percentage inhibition of 65%). Both compounds **XXIIe** and **XLd** displayed an IC_{50} against aromatase enzyme of 2.6 and 3.1 μ M respectively.

To further exploit anti-tumor effect of compound **XXIIe** in T47D cell line; Level of caspase 3 RNA for compound **XXIIe** was measured. Caspase3 levels; one of the crucial mediators of apoptosis in cancer cells, were elevated by 92 thousand folds upon treatment with **XXIIe** compared to the control. These results confirmed that (**XXIIe**) exhibited its antiproliferative activity against breast cancer cell line T47D via induction of apoptosis revealed in elevated Caspase3 levels as well as inhibition of aromatase enzyme

Finally, a thorough Molecular docking, using C-DOCKER protocol in Discovery Studio 3.5 Software, was attempted to investigate the binding mode of the targeted compounds and interpret their variable inhibitory activity. Computer aided ADMET study was also performed using the same software.

Abstract

This study involved the synthesis of the following unavailable reported intermediates:

1. 1-(3,4-Dichlorophenyl)-3-(3-nitrophenyl)urea **(Ia)**
2. 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(3-nitrophenyl)urea **(Ib)**
3. 1-(3-Aminophenyl)-3-(3,4-dichlorophenyl)urea **(IIa)**
4. 1-(3-Aminophenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea **(IIb)**
5. 1-(3,4-Dichlorophenyl)-3-(4-nitrophenyl)urea **(IIIa)**
6. 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-nitrophenyl)urea **(IIIb)**
7. 1-(3,5-Dimethoxyphenyl)-3-(4-nitrophenyl)urea **(IIIc)**
8. 1-(4-Aminophenyl)-3-(3,4-dichlorophenyl)urea **(IVa)**
9. 1-(4-Aminophenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea **(IVb)**
10. 1-(4-Aminophenyl)-3-(3,5-dimethoxyphenyl)urea **(IVc)**
11. 3-(3,4-Dichlorobenzyl)-6-nitrobenzo[d]thiazol-2(3H)-one **(VIa)**
12. 3-(3-Bromobenzyl)-6-nitrobenzo[d]thiazol-2(3H)-one **(VIb)**
13. 6-Amino-3-(3,4-dichlorobenzyl)benzothiazol-2(3H)-one **(VIIa)**
14. 6-Amino-3-(3-bromobenzyl)benzothiazol-2(3H)-one **(VIIb)**
15. 1H-Indazol-5-amine **(IX)**
16. 1,2-Dihydropyridazine-3,6-dione **(X)**
17. 3,6-Dichloropyridazine **(XI)**
18. 3-Chloro-6-hydrazinylpyridazine **(XV)**
19. 6-Chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-amine **(XVI)**
20. 6-[1,2,4]Triazolo[4,3-b]pyridazin-3-amine **(XVIII)**
21. 6-(4-Nitrophenyl)pyridazin-3(2H)-one **(XX)**
22. 6-(4-Aminophenyl)pyridazin-3(2H)-one **(XXI)**
23. 3-Nitro acetophenone **(XXIII)**
24. 6-(3-Nitrophenyl)pyridazin-3(2H)-one **(XXIV)**
25. 6-(3-Aminophenyl)pyridazin-3(2H)-one **(XXV)**
26. N-(4-((6-Chloropyridazin-3-yl)oxy)phenyl)acetamide **(XXVII)**
27. 6-(4-Aminophenoxy)pyridazin-3(2H)-one **(XXVIII)**
28. 4-((6-Chloropyridazin-3-yl)amino)benzoic acid **(XXXVIII)**

Abstract

29. 6-Methoxy-N-(4-nitrophenyl)pyridazin-3-amine (**XXXV**)

30. N1-(6-methoxypyridazin-3-yl)benzene-1,4-diamine (**XXXVI**)

Also, it comprised the following new intermediates:

1. 1-(3,5-Dimethoxyphenyl)-3-(3-nitrophenyl)urea (**Ic**)
2. 1-(3-Aminophenyl)-3-(3,5-dimethoxyphenyl)urea (**IIc**)
3. N-(6-Chloropyridazin-3-yl)-1H-indazol-5-amine (**XXXII**)

In addition, the study involved the synthesis and the characterization of the following new-targeted compounds:

1. 1-(3,5-Dimethoxyphenyl)-3-(pyridazin-3-yl)urea (**XIVa**)
2. 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(pyridazin-3-yl)urea (**XIVb**)
3. 1-(6-Chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-3-(3,4-dichlorophenyl)urea (**XVII**)
4. 1-(3,4-Dichlorophenyl)-3-(6-morpholino-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)urea (**XIXa**)
5. 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(6-morpholino-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)urea (**XIXb**)
6. 1-(3-Methoxyphenyl)-3-(6-morpholino-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)urea (**XIXc**)
7. 1-(3,4-Dichlorophenyl)-3-(4-(6-oxo-1,6-dihydropyridazin-3-yl)phenyl)urea (**XXIIa**)
8. 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(6-oxo-1,6-dihydropyridazin-3-yl)phenyl) urea (**XXIIb**)
9. 1-(4-Chloro-2-methylphenyl)-3-(4-(6-oxo-1,6-dihydropyridazin-3-yl)phenyl)urea (**XXIIc**)
10. 1-(4-Chlorophenyl)-3-(4-(6-oxo-1,6-dihydropyridazin-3-yl)phenyl)urea (**XXIId**)
11. 1-(4-(6-Oxo-1,6-dihydropyridazin-3-yl)phenyl)-3-(4-(trifluoromethyl)phenyl)urea (**XXIIe**)
12. 1-(4-(6-Oxo-1,6-dihydropyridazin-3-yl)phenyl)-3-(3-(methoxy)phenyl)urea (**XXIIIf**)
13. 1-(3,4-Dichlorophenyl)-3-(3-(6-oxo-1,6-dihydropyridazin-3-yl)phenyl) urea (**XXVIa**)